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Abstract: Ca2+-transcription coupling controls gene expression patterns that define vascular smooth 
muscle cell (VSMC) phenotype. Although not well understood this allows normally contractile VSMCs to 
become proliferative following vessel injury, a process essential for repair but which also contributes to 
vascular remodelling, atherogenesis and restenosis. Here we show that the Ca2+/HCO3--sensitive enzyme, 
soluble adenylyl cyclase (sAC), links Ca2+ influx in human coronary artery smooth muscle cells (hCASMCs) 
to 3',5'-cyclic adenosine monophosphate (cAMP) generation and phosphorylation of the transcription factor 
Ca2+/cAMP response element binding protein (CREB).  Store-operated Ca2+ entry (SOCE) into hCASMCs 
expressing the FRET-based cAMP biosensor H187 induced a rise in cAMP that mirrored cytosolic [Ca2+].  
SOCE also activated the cAMP effector, protein kinase A (PKA), as determined by the PKA reporter, 
AKAR4-NES, and induced phosphorylation of vasodilator-stimulated phosphoprotein (VASP) and CREB.  
Transmembrane adenylyl cyclase inhibition had no effect on the SOCE-induced rise in cAMP, while sAC 
inhibition abolished SOCE-generated cAMP and significantly reduced SOCE-induced VASP and CREB 
phosphorylation.  This suggests that SOCE in hCASMCs activates sAC which in turn activates the 
cAMP/PKA/CREB axis.   sAC, which is insensitive to G-protein modulation but responsive to Ca2+, pH and 
ATP, may therefore act as an overlooked regulatory node in vascular Ca2+-transcription coupling. 
  
Introduction 
In healthy blood vessels, the majority of vascular smooth muscle cells (VSMCs) are quiescent, contractile 
and proliferate slowly 1.  Quiescent VSMCs change to a synthetically active and proliferative phenotype in 
response to stimuli such as mechanical stress, growth factors or inflammatory mediators 2. This plasticity 
is important for vessel repair at times of vascular injury, but is also a central feature of vascular disease. 
Proliferation of VSMCs in the vessel wall contributes to atherogenesis, vascular remodelling in pulmonary 
hypertension, and to restenosis, a narrowing of the vessel lumen following balloon angioplasty and bypass 
vein grafting 3-5.  The altered pattern of gene expression that drives changes in VSMC phenotype correlates 
with different patterns of Ca2+ signaling 6, 7, although the molecular basis of Ca2+-regulated gene expression 
in VSMCs is not well understood. 
Ca2+-induced gene expression can be mediated in VSMCs by the transcription factor Ca2+/cyclic AMP 
response element binding protein (CREB) 6.  CREB binds as a dimer to a conserved cyclic AMP response 
element (CRE) in the promoter of pro-survival genes and activates transcription in response to a variety of 
diverse extracellular signals 8.  Multiple Ca2+-regulated signaling cascades converge to phosphorylate 
CREB at a critical Ser133 residue, which induces recruitment of coactivators and the formation of an active 
transcriptional complex 9.  Ser133 is a substrate for a number of kinases that are either directly or indirectly 
activated by Ca2+, including protein kinase A (PKA), protein kinase C, members of the calcium/calmodulin-
dependent kinase (CaMK) family and ribosomal S6 kinase (RSK) -2 6. Intriguingly, Ca2+ signals from 
different sources trigger different patterns of CRE-regulated VSM gene expression 10.  Voltage-dependent 
Ca2+ influx through L-type Ca2+ channels induces CREB phosphorylation in both cultured VSMCs and in 
intact mouse cerebral arteries 11, 12 and correlates with an increase in transcription of proliferation-
associated CRE-containing genes such as c-fos and early growth response-1, egr-1 10-12.  In agreement 
with this, cerebral arteries from hypertensive rats are depolarized compared to normotensive animals and 
have elevated cytosolic Ca2+ and increased CREB phosphorylation/c-fos expression, which can be 
reversed by L-type Ca2+ channel inhibition 13.   Ca2+ influx in response to depletion of the sarcoplasmic 
reticulum (SR) Ca2+ stores (store-operated Ca2+ entry, SOCE) also activates CREB in both cultured VSMCs 
and intact arteries.  Here, CREB activation leads to the transcription of a set of CRE-regulated genes that 
overlaps, but is distinct from, the genes expressed following L-type Ca2+ channel activation   10, 14.  Several 
transient receptor potential (TRP) channels as well as the Ca2+ release-activated channel protein 1 (Orai1) 
and the SR Ca2+ sensor stromal interaction molecule 1 (STIM1) are expressed in VSM and may mediate 
SOCE 15, 16.   Orai1 and STIM1 are both upregulated in response to vascular injury 17 and are also required 
for the activation of CREB involved in VSMC proliferation 18. In line with this, STIM1 knockdown decreases 
SOCE-induced CREB activation in human coronary artery SMCs and suppresses cell growth 19.  STIM2 is 
also upregulated in pulmonary artery hypertension, which raises basal Ca2+ levels and enhances pulmonary 
artery VSMC proliferation and vascular remodelling at least partially through activation CREB 20.   Indeed, 
inhibition of Orai-mediated Ca2+ entry and the resultant suppression of Ca2+-transcription coupling has been 
suggested to underlie the anti-proliferative effects of stent-coating drug sirolimus (rapamycin) in human 
arteries 21.  
 
In cultured VSMCs CREB activation is associated with both pro- 22-25, and anti-proliferative outcomes 26, 27, 
and this complex behaviour is also reflected in vivo.  In rat models, phospho-CREB is elevated in neointimal 
VSMCs that appear after balloon injury of the carotid artery 28, and increased phospho-CREB levels 
correlate with high proliferation rates in cerebral artery following several forms of vessel injury linked with 
susceptibility to stroke 29.  In contrast, analysis of arteries taken from bovine systemic and pulmonary 
circulation show a reverse correlation between CREB phosphorylation and proliferation, with phospho-
CREB high in quiescent, contractile smooth muscle cells from the healthy vessel’s medial layer 30. Here, 
chronic exposure of animals to lower than normal oxygen levels leads to increased VSMC proliferation in 
pulmonary vessels and decreased levels of both CREB and phospho-CREB 30.  This highlights our 
incomplete understanding of how different environmental cues are integrated by VSMCs to activate gene 
transcription.   
The current model for PKA-mediated phosphorylation of CREB in VSMCs is that Ca2+ entering the cytosol 
binds to calmodulin (CaM) and that the Ca2+/CaM complex then activates Ca2+-sensitive transmembrane 
adenylyl cyclases (tmACs), leading to generation of cyclic AMP and the activation of PKA 8.  An alternative 
source of cyclic AMP comes from soluble adenylyl cyclase (sAC), a novel enzyme that lacks the two 
hydrophobic domains that embed tmACs in the membrane and which thus distributes about the cell in 
regions remote from the plasma membrane 31. Here, we demonstrate that SOCE activates sAC to generate 
cyclic AMP and induce phosphorylation of CREB at Ser133 in human coronary artery smooth muscle cells.  
sAC is insensitive to G-protein modulation and forskolin activation, but directly activated by Ca2+ 
(independently of CaM) and HCO3- and responds to physiologically relevant ATP concentrations 32. Since 
CO2 is in equilibrium with HCO3- due to the activity of carbonic anhydrases, sAC functions as a CO2/ HCO3-
, and thus indirect pH sensor.  This ability to sense and integrate fluctuations in intracellular signals suggests 
sAC may be an important and overlooked regulatory node in the VSMC Ca2+-transcription pathway.   
 
Results  
SOCE increases intracellular cyclic AMP and activates PKA in human coronary artery smooth 
muscle cells (hCASMCs)  
To generate store-operated Ca2+ entry (SOCE), hCASMC internal Ca2+ stores were depleted by bathing 
fura-2-AM-loaded cells in nominally Ca2+-free solution for 10 minutes before addition of the sarcoplasmic 
reticulum Ca2+ ATPase (SERCA) inhibitor, thapsigargin (TG, 2μM) to the same solution.  Ca2+ leaks 
passively from the stores through permanently open leak channels and is subsequently removed from the 
cytosol either by extrusion across the plasma membrane or reuptake into the stores by SERCA.  Inhibition 
of SERCA thus blocks reuptake and causes a transient rise in intracellular Ca2+ as leak Ca2+ briefly builds 
up in the cytosol before being moved out of the cell by plasma membrane Ca2+ ATPases (Figure 1a). Over 
time this process depletes Ca2+ stores.  Subsequent addition of Ca2+ (1.8mM) to the extracellular solution 
induces a rapid rise in cytosolic Ca2+ due to SOCE (Figure 1a).  hCASMCs transduced with adenoviruses 
encoding the FRET-based cyclic AMP biosensor H187 and exposed to the same protocol exhibit changes 
in intracellular cyclic AMP that essentially mirror the cytosolic Ca2+ increase induced by the addition of 
thapsigargin and by SOCE (Figure 1b).  As a control, saturating concentrations of the transmembrane 
adenylyl cyclase activator, forskolin, (20μM) and the pan-phosphodiesterase inhibitor, IBMX, (500μM) were 
added at the end of each experiment to generate maximal cyclic AMP responses. These intracellular 
increases in cyclic AMP activated the major downstream cyclic AMP effector, protein kinase A (PKA). PKA 
activity was measured in real-time in hCASMCs transduced with adenoviruses encoding the PKA reporter, 
AKAR4-NES (Figure 1c). PKA activity was also monitored by immunoblot to determine the phosphorylation 
status of multiple PKA substrates (PKA substrate antibody detects proteins containing a phospho-Ser/Thr 
residue within the PKA recognition motif Arg-Arg-X-Ser/Thr) and of the specific PKA substrate, vasodilator-
stimulated phosphoprotein (VASP) 33, 34 (Figure 1d).    
 
SOCE-generated cyclic AMP is abolished by acute inhibition of soluble adenylyl cyclase. 
The Ca2+ sensitivity of some isoforms of the enzyme adenylyl cyclase is a well-defined mechanism linking 
Ca2+ influx to the generation of cyclic AMP 35.  Mammals express nine transmembrane isoforms of adenylyl 
cyclase (tmAC1-9) and one soluble isoform (sAC; AC10), which are differentially regulated by Ca2+ 36.   AC5 
and AC6 are inhibited by sub-micromolar concentrations of Ca2+ while AC1 and AC8, and to a lesser extent 
AC3, are stimulated by Ca2+ via calmodulin binding 36. Consistent with other findings 37 38, 39, reverse 
transcription-PCR, using cDNA derived from hCASMCs as a template and primers designed to detect AC 
isoforms 1-10, confirmed the presence of transcripts for AC3, 4, 6, 7, 9 and 10 (Figure 2a).   Since AC3 
has been reported to be weakly activated by Ca2+/calmodulin 40 we tested the effect of acutely inhibiting 
tmACs on the SOCE-generated cyclic AMP.  2’-5’ dideoxyadenosine (DDA) is a well-characterised cell-
permeable pharmacological tool for distinguishing between tmACs and sAC.  In whole-cell lysates DDA 
inhibits tmACs with an IC50 of ~10μM and sAC with an IC50 of over 500μΜ 41.    Preincubation of hCASMCs 
in DDA (100μM) significantly reduced the transient increase in cyclic AMP seen upon addition of 
thapsigargin, but had no effect on SOCE-generated cyclic AMP (Figure 2b).  In parallel control 
experiments, addition of DDA (100μM) induced a significant reduction in cyclic AMP generated in response 
to prostacyclin (PGI2; 1nM, Figure 2c).  Pre-incubation with the catechol estrogens, 2-hydroxyestradiol (2-
CE, 20μM) or 4-hydroxyestradiol (4-CE, 20μM), which in cell-based systems are selective sAC inhibitors 
41, completely abolished generation of cyclic AMP in response to both the addition of thapsigargin and 
SOCE (Figure 2d-e).   Aside from effects on sAC, 2CE and 4CE could potentially block the production of 
cyclic AMP by inhibiting Ca2+ entry into the cell. Since 2CE has previously been shown to inhibit voltage-
gated Ca2+ influx in pig coronary arteries 42, we assessed the effects of 2CE and 4CE on SOCE.   Exposure 
of hCASMCs to either 2CE or 4CE did not inhibit Ca2+ entry following thapsigargin-induced store depletion 
and the reintroduction of extracellular Ca2+ (Figure 2f). 
 
Inhibition of soluble adenylyl cyclase abolishes SOCE-induced VASP phosphorylation 
In line with our FRET-based studies, pre-incubation of cells with 2CE (20μM) or 4CE (20μM) significantly 
reduced SOCE-induced phosphorylation of VASP (Figure 3 a-b).  For these experiments, we exposed 
hCASMCs to the thapsigargin-induced store depletion/ Ca2+ reintroduction protocol (Figures 1-2) in the 
presence or absence of AC inhibitors, lysed cells and analysed lysates by immunoblot using antibodies 
against VASP.  We also tested the effects of KH7, a selective inhibitor of sAC with intrinsic fluorescence 
that makes it unsuitable for use in fluorescent microscopy. In whole cell lysates KH7 inhibits sAC with an 
IC50 of 20μM while having no significant effect on tmAC activity at concentrations up to 1mM 41.  Pre-
incubation with KH7 (20μM) significantly reduced SOCE-induced VASP phosphorylation (Figure 3 c-d).  
The effect of DDA (100μM) on SOCE-induced VASP phosphorylation did not reach significance. 
 
Cyclic AMP generated by soluble adenylyl cyclase in response to SOCE phosphorylates CREB 
To assess the downstream consequences of SOCE-generated cyclic AMP, we also analysed hCASMC 
lysates by immunoblot using antibodies specific to CREB’s Ser133 phospho-site (Figure 4).   Figure 4 a, c 
(lanes 1-2) shows that thapsigargin-induced store depletion followed by addition of Ca2+ (1.8mM) to the 
extracellular solution induces significant phosphorylation of CREB at Ser 133.  Pre-incubation with the 
catechol estrogens 2CE and 4CE (Figure 4a-b), or KH7 (Figure 4c-d), significantly reduced SOCE-induced 
CREB phosphorylation.   
 
Discussion  
Our data suggest that Ca2+ influx in response to hCASMC store depletion activates the Ca2+ and HCO3--
sensitive enzyme, sAC, which generates cyclic AMP to activate the PKA/CREB axis.   Intracellular cyclic 
AMP levels in hCASMCs largely mirrored the changes in cytosolic free Ca2+ seen during thapsigargin-
induced store depletion and subsequent SOCE.   Inhibition of tmACs significantly reduced the intracellular 
increases in cyclic AMP seen during thapsigargin-induced store depletion, but had no significant effect on 
SOCE-generated cyclic AMP.  In agreement with other studies, we found no evidence for expression of the 
Ca2+-activated AC1 or AC8 in these cells, although we did find transcripts for AC3, which is weakly activated 
by Ca2+ (half-maximal activation 5M) 40.  Acute inhibition of sAC abolished the intracellular increases in 
cyclic AMP seen during thapsigargin-induced store depletion and subsequent SOCE, suggesting that 
activation of sAC is a prerequisite for cyclic AMP generation via both processes.  To our knowledge, SOCE 
has not previously been reported to activate sAC, although Ca2+ influx through voltage-gated Ca2+ channels 
activates sAC in insulinoma cells 43.    
 
By using biosensors to monitor real-time changes in the activity of the major cyclic AMP effector, PKA, our 
data also show that SOCE/sAC-generated cyclic AMP activates PKA.  This induces phosphorylation of a 
number of PKA substrates within the cell, including VASP and the transcription factor, CREB.  Previous 
studies have shown that Ca2+ influx through store-operated channels activates CREB and induces 
transcription of a distinct set of genes in VSMCs 10, but the pool of cyclic AMP responsible for PKA-mediated 
CREB activation was believed to be generated by exclusively  tmACs.  More recent work shows that CREB 
can mediate both pro- and anti-mitogenic responses in VSMCs dependent upon different modes of 
activation 44.  Activation of CREB by cyclic AMP generated by either forskolin or agonists at G protein-
coupled receptors (both of which exclusively activate tmACs) is independent of Ser133 phosphorylation but 
dependent on nuclear translocation of CREB Regulated Transcription Coactivators (CRTCs) 44 45.  This 
form of CREB activation is anti-proliferative. In contrast, stimulation of VSMCs by mitogens significantly 
increases CREB activity via Ser133 phosphorylation but not CRTC activation. CREB activated by this 
mechanism induces pro-mitogenic responses since CREB silencing under these circumstances inhibits 
basal and growth factor-induced proliferation 44.   Our studies, which were conducted in the presence of 
serum and show Ser133 phosphorylation, suggest that sAC-generated cyclic AMP may contribute to this 
latter pro-proliferative pathway. 
Compared to the relatively well-studied tmACs, our knowledge of the role of sAC in the vasculature is 
limited.  Although widely expressed throughout the cardiovascular system 46, the only previously reported 
role for vascular sAC involves activation by oxidative stress to promote the intrinsic apoptotic pathway 47.  
Similar roles in apoptotic signaling have been described in coronary endothelial cells 48 and cardiomyocytes 
49.   In cardiomyocytes there is evidence of roles for sAC outside of death pathways in the development of 
cardiac hypertrophy 50, and in matching energy production to nutrient levels in mitochondria 51.  Here, 
CO2/HCO3- generated by the citric acid cycle activates sAC localized in the matrix to produce cyclic AMP, 
which mediates a PKA-dependent increase in the activity of the electron transport chain and oxidative 
phosphorylation 51 52.   A source of cyclic AMP that is distinct from the G-protein-responsive plasma 
membrane-localized tmACs is likely to be an important general feature in signaling.   Cyclic AMP has a 
limited diffusion distance largely due to the action of phosphodiesterases that restrict its spread throughout 
the cell to ensure the fidelity of signal transfer to intended targets 53.  sAC is able to locate to several 
intracellular compartments, including the cytosol, the nucleus 54, and the mitochondria 51, 55.  Indeed, in skin 
cells, sAC localizes to the nucleus where it complexes with CREB 56.  Zippin et al demonstrated the 
existence of a functional signaling complex consisting of sAC, the PKA holoenzyme and CREB in the 
nucleus of human cell lines and in a subpopulation of rat liver cells 54.  This complex ensures rapid CREB 
activation in response to changes in HCO3- and was distinct from the slower hormone or neurotransmitter 
CREB activation via tmACs.   
 
In conclusion, our data suggest that in hCASMCs SOCE activates the Ca2+ and HCO3--sensitive sAC, which 
generates cyclic AMP to activate the PKA/CREB axis. A source of cyclic AMP that is remote from the 
plasma membrane may allow sAC access to pools activators and effectors that are distinct from the 
membrane-confined tmAC microdomains. This coupled with its ability to respond rapidly to changes in the 
intracellular environment suggests it may act as a regulatory point in VSMC Ca2+-transcription coupling.  
Although the functional consequences of sAC-induced CREB phosphorylation are undetermined, recent 
evidence suggests it may link to pro-mitogenic responses in VSMCs 44.  A single gene encodes sAC, which 
is widely expressed in mammalian tissues 31. Alternative splicing generates multiple sAC isoforms 57, 
suggesting that VSMC sAC may warrant investigation as a potentially novel drug target for proliferative 
vascular disease.  It will also be important to determine if specific subsets of phosphodiesterases control 
the dispersal of sAC-generated cyclic AMP in VSMCs as these ‘druggable’ targets may offer an additional 
route to manipulate the signaling pathway. 
 
Materials and Methods 
Chemicals  
2’-5’dideoxyadenosine (DDA) and thapsigarin were purchased from Merck Millipore (Watford, UK). (6)-2-
(1H-benzimidazol-2-ylthio)propanoic acid 2-[(5-bromo-2-hydroxyphenyl)methylene]hydrazide (KH7) and 
forskolin were purchased from Tocris Bioscience (Abingdon, UK). Fura-2-AM and Fluo-4 AM was 
purchased from ThermoFisher Scientific (Paisley, UK). All other chemicals, including 2-hydroxyestradiol (2-
CE), 4-hydroxyestradiol (4-CE), and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma 
Aldrich (Gillingham, UK). 
 
Cell culture 
Human coronary artery smooth muscle cells (hCASMCs; Promocell, Heidelberg, Germany) were cultured 
in smooth muscle cell growth medium 2 containing 5 % (v/v) foetal calf serum supplemented with basic 
fibroblast growth factor (2 ng mL-1), epidermal growth factor (0.5ng mL-1) and insulin (5μg mL-1; all 
Promocell). Cells between passages 6-12 were cultured in a humidified incubator at 37°C and 5 % CO2 
atmosphere, with culture media changed every 2-3 days. Cells were routinely sub-cultured at 70-80% 
confluency.  
 
Adenovirus Transduction 
Adenoviruses encoding H187 [AD(RGD)-CMV-H187] and AKAR4 [AD(RGD)-CMV-AKAR4-NES] were 
cloned, packaged, amplified and titrated by Vector Biosystems Inc (Malvern, PA, USA). For FRET-based 
imaging studies, viral particles of either AD(RGD)-CMV-H187 or AD(RGD)-CMV-AKAR4 in a solution 
containing Dulbecco's Modified Eagle Medium (DMEM; Gibco ThermoFisher Scientific), 2% (v/v) bovine 
serum albumin (BSA; Invitrogen, ThermoFisher Scientific) and 2.5% (v/v) glycerol,  were added directly to 
hCASMC suspensions at 10 MOI (multiplicity of infection).  Cells were then seeded onto glass-bottomed 
culture dishes (Mattek Inc., Bratislava, Slovakia) for imaging 24 or 48 hours later.  
 
Förster resonance energy transfer (FRET)-based biosensors and fluorescence imaging 
Real-time cyclic AMP changes were measured in live hCASMCs transduced with adenoviruses encoding 
the biosensor H187 (mTurquoise2Δ-Epac(CD,ΔDEP,Q270E)-tdcp173Venus (plasmid used for adenoviral 
construction a gift from Kees Jalink, Univ of Amsterdam, Netherlands) 58. This sensor consists of the cAMP 
effector Epac1 fused to a cyan fluorescent protein (CFP) donor (mTurquoise2) and an optimized yellow 
fluorescent protein (YFP) acceptor (a tandem of the circular permutated version of Venus, cp173Venus). 
Binding of cAMP causes a conformational change resulting in a loss of energy transfer between the two 
ﬂuorophores that can be detected as an increase in the CFP/YFP ﬂuorescence ratio. To prevent construct 
enzymatic activity affecting downstream effector, Epac has been rendered catalytically dead (CD) and a 
membrane-targeting domain is deleted (ΔDEPmutant) to allow measurement of cAMP in the bulk cytosol. 
Real-time PKA catalytic activity was measured in hCASMCs using the FRET-based PKA reporter A-Kinase 
Activity Reporter-Nuclear Export Signal, AKAR4-NES 59 (a gift from Jin Zhang, John Hopkins University, 
Baltimore, USA). AKAR4 contains a PKA substrate and a phospho-amino acid binding domain (PAABD) 
between the FRET pair Cerulean and Venus.  The PAABD binds to the PKA substrate when it is 
phosphorylated by active PKA, causing a decrease in distance between the fluorophores and an increase 
in FRET.  Prior to each experiment, H187 and AKAR4-expressing hCASMCs were rinsed twice in a Na+-
HEPES-based solution containing (mM): 140 NaCl, 4.7 KCl, 1.13 MgCl2, 10 HEPES, and 10 glucose (all 
purchased from Sigma Aldrich); adjusted to pH 7.4 (referred to as HEPES solution hereafter). This HEPES 
solution was also supplemented with 1% (v/v) foetal calf serum (0.4 ng mL-1), epidermal growth factor (0.1 
ng mL-1), insulin (1 μg mL-1) and 1.8 mM CaCl2 unless stated otherwise. All test solutions, including controls, 
were made using this HEPES solution.   
Cells were imaged using an Olympus IX71 based inverted imaging system (Till Photonics GmbH, 
Germany). Excitation of fluorescence was provided by a 150W xenon high stability lamp and a polychrome 
V monochromator wavelength control (Till Photonics GmbH, Germany). Emission light was collected using 
band or high pass filters and sent to an iXon DV885 cooled EM CCD camera (Andor technology, UK). 
Camera binning was set to 2 both horizontally and vertically which provided 512x512 pixel points per image. 
TillVision software (Till Photonics, Germany) was used to control the parameters of image acquisition, 
selection of regions of interest and post-analysis, and allowed for the measurement of fluorescence while 
the experiment was in progress.  H187 and AKAR4-expressing hCASMCs were both excited at 405nm, 
close to the excitation maximum of the donor, CFP. Emissions of both CFP and YFP fluorescence were 
measured simultaneously using an Optical Insights Dual-View Filter cube with D480 + 30m and D535 + 
40m Filter Sets, (BioVision Technologies, USA) which only allows emission wavelengths of 480nm and 
535nm to reach the camera. During each experiment non-fluorescent cells or regions containing no cells 
were used as background fluorescence from which the reading was subtracted.  
 
Ca2+ fluorimetry 
hCASMCs were incubated in 5 µM of the ratiometric Ca2+ dye Fura-2 AM dissolved in HEPES solution for 
1 hour at room temperature in the dark. Fura-2 AM-loaded cells were then rinsed twice with HEPES solution, 
before being placed into the perfusion chamber for live cell imaging using the Olympus IX71 based inverted 
imaging system (above). The cell was illuminated alternately with 340 and 380 nm light (bandpass 5 nm) 
and the emission signal was detected at 510 nm (40 nm bandpass).  Temporal change in photon counts 
was measured, backgrounds were subtracted, and the complete ratio was obtained at 50 Hz. As in FRET 
experiments, cells that were not fluorescent or regions containing no cells were used as background from 
which the reading was subtracted.   For indicated experiments, cells were incubated with 5 µM Fluo-4 AM 
in glass-bottomed dishes (Ibidi GmbH, Germany), washed as described above and imaged using a Zeiss 
LSM 710 confocal microscope. Cells were excited with 488 nm light and the emission signal was detected 
within a range of 493-622 nm. 
 
SDS-PAGE and Immunoblotting 
hCASMCs were seeded onto 6-well plates and allowed to grow at 37°C and 5% CO2 atmosphere until 
reaching 70-80% confluence.    Cells were then incubated in vehicle control (0.1% DMSO) or incubated in 
zero extracellular Ca2+ for 5 mins before being treated with thapsigargin (TG, 2μM) for 5 min in zero 
extracellular Ca2+ followed by introduction of 1.8mM extracellular CaCl2 for a further 5 min. As a positive 
control cells were exposed to saturating concentrations of forskolin (20μM) and IBMX (500μM) only. In 
some experiments, cells were incubated in the tmAC inhibitor DDA (100μM) or the sAC inhibitors KH7 or 
2CE or 4CE (20μM) for at least 15 minutes before TG treatment. Inhibitors were then present throughout 
the experiment.  The solution used for drug treatments was the same supplemented HEPES solution used 
for fluorescent imaging. Following each treatment, cells were then lysed in ice-cold 
radioimmunoprecipitation assay (RIPA) buffer containing 1% (v/v) protease inhibitor cocktail and 1x 
PhosSTOP phosphatase inhibitor cocktail (both Sigma-Aldrich). The resultant lysates were rotated for 15 
minutes at 4oC and then centrifuged at 18,220 x g for 15 minutes at 4 °C.  Resultant supernatants were 
mixed 1:3 (v/v) with 4x sodium dodecyl sulfate-polyacrylamide (SDS) sample buffer, before heating to 98oC 
for 10 minutes. Protein concentrations were quantified using a PierceTM BCA Protein Assay Kit 
(Thermofisher Scientific). Samples were kept at -20oC until use. Proteins within the lysates were resolved 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 10-15% polyacrylamide gels and transferred 
electrophoretically onto nitrocellulose membranes (Hybond ECL, GE Healthcare). Immunoblotting was 
performed as previously described 60.  
 
Antibodies 
For immunoblotting the primary antibodies used were against: total CREB, vasodilator-stimulated 
phosphoprotein (VASP) and phospho-PKA substrates (RRXS*/T*); all purchased from Cell Signaling 
Technologies (Hitchin, UK) and used at a dilution of 1:1000.  Anti-smooth muscle α actin (dilution 1:10,000) 
was from Sigma-Aldrich.  Anti-phospho-CREB (Ser133, dilution 1:1000) and anti-GAPDH (1: 2000) were 
purchased from Abcam (Cambridge, UK).  The secondary antibodies used were: anti-mouse IgG (H+L) 
horseradish peroxidase (HRP) conjugated polyclonal antibody and anti-rabbit IgG (H+L) HRP conjugated 
polyclonal antibody (Stratech Scientific Ltd., Newmarket, U.K.), both used at a dilution of 1:5000. 
 
Total RNA extraction and reverse transcription 
Total RNA extraction and reverse transcription was carried out as previously described 61. 
Polymerase Chain Reaction (PCR) 
Touchdown PCR was carried out as previously described 61.  Primers used to amplify specific adenylyl 
cyclase isoforms were previously published 62. Products were analysed by running on a 3% agarose gel 
containing Midori Green (1:10,000; GC Biotech) for ~1 hour at 80V. Bands were excised under ultraviolet 
light and products purified using a QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. All products were verified by sequencing (GATC Biotech, Germany). 
Statistical Analysis 
Statistical tests stated throughout. Results are expressed as the mean ± standard error of mean. For real-
time Ca2+/cyclic AMP measurements, n numbers indicate number of cells from at least 3 experimental 
repeats conducted on separate days.  For immunoblots n numbers indicate number of experimental 
repeats. 
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Figure Legends:  
 
Figure 1. SOCE increases intracellular cyclic AMP and activates PKA in human coronary artery 
smooth muscle cells (hCASMCs).  a; Intracellular Ca2+ measurements recorded in fura-2-AM-loaded 
hCASMCs. Cells were initially bathed in nominally Ca2+-free solution for 10 minutes before treatment with 
thapsigargin (TG, 2μM). Ca2+ (1.8mM) was then introduced into the extracellular solution and was present 
hereafter (n=54 from 4 experimental repeats). b; Intracellular cyclic AMP levels measured in hCASMCs 
transduced with adenoviruses encoding the cyclic AMP biosensor H187 (upper panel, see Methods for 
details) and subjected to the same experimental scheme as described in a. At the end of the experiment 
saturating concentrations of forskolin (20μM) and IBMX (500μM) were added to generate maximal cyclic 
AMP responses (n=20 cells from 4 experimental repeats). c; PKA activity measured in hCASMCs 
transduced with adenoviruses encoding the PKA reporter, AKAR4-NES (upper panel, see Methods for 
details) in response to the experimental scheme described in a (n=19 cells from 4 experimental repeats). 
All extracellular solutions contain 1% serum. Error bars represent the standard error of the mean. d; 
Western blot analyses of hCASMC homogenates immunoblotted with anti-VASP (upper panel) and anti-
phospho-PKA substrates (lower panel).  Before being lysed, cells were exposed to either: vehicle control 
(0.1% DMSO); thapsigargin (TG, 2μM) for 5 min in zero extracellular Ca2+, TG for 5 min in zero extracellular 
Ca2+ followed by introduction of 1.8mM extracellular Ca2+ for a further 5 min; or forskolin (20μM) plus IBMX 
(500μM) for 5 min.  In lysates immunoblotted with anti-VASP, phosphorylated VASP appears as a slower-
migrating band. Maximal phosphorylation is seen following exposure to saturating concentrations of 
forskolin and IBMX.  Blots shown representative of 3 experimental repeats. e. Densiometric analysis; the 
density of the phospho-VASP immunoreactive band relative to the lower (unphosphorylated) VASP band 
(n=3, Control vs TG/0Ca2+: P=0.024; Control vs TG/1.8Ca2+: P=0.026; Control vs Fsk/IBMX: P=0.001; one-
way ANOVA with Student Newman Keuls post-hoc test).  
 
Figure 2. SOCE-generated cyclic AMP is abolished by inhibition of soluble adenylyl cyclase.    a. 
Primers designed to amplify adenylyl cyclase isoforms (1-10) were used to probe hCASMC cDNA.  PCR 
products were separated on a 3% agarose gel. b-e. hCASMCs transduced with adenoviruses encoding the 
cyclic AMP biosensor H187 and subjected to the same experimental scheme as described in Figure 1.  
Cells were pre-incubated in either vehicle control (0.1% DMSO; black all traces); the transmembrane 
adenylyl cyclase inhibitor 2’-5’ dideoxyadenosine (DDA, 100μM, n=48 from 4 experimental repeats, b); or 
soluble adenylyl cyclase inhibitors 2-hydroxyestradiol (2-CE, 20μM, n=29 from 4 experimental repeats d) 
or 4-hydroxyestradiol (4-CE, 20μM, n=18 from 4 experimental repeats, e) for at least 10 minutes before 
addition of thapsigargin (TG, 2μM).  Inhibitors were then present until addition of forskolin (20μM) and IBMX 
(500μM) and the paired controls were conducted on the same day as the test. c. As a positive control, 
addition of DDA (100μM) induced a significant reduction in cyclic AMP generated in response to 
prostacyclin (PGI2; 1nM, n=24 from 4 experimental repeats). Error bars represent the standard error of the 
mean.   f.  Store-operated Ca2+ entry recorded in Fluo-4AM-loaded hCASMCs under control conditions and 
in the presence of either 2-CE and 4-CE (20μM). Cells were initially bathed in nominally Ca2+-free solution 
for 10 minutes before treatment with thapsigargin (TG, 2μM). Ca2+ (1.8mM) was then introduced into the 
extracellular solution (control, n=90 cells; 2-CE, n=65 cells; 4-CE, n=89 cells).  Error bars represent the 
standard error of the mean.   
 
Figure 3. Inhibition of soluble adenylyl cyclase abolishes SOCE-induced VASP phosphorylation 
Immunoblot blot analyses of hCASMC homogenates immunoblotted with anti-VASP and anti-GAPDH 
(loading control).    Before being lysed, cells were exposed to either: vehicle control (0.1% DMSO, Lane 1 
both blots) or thapsigargin (TG, 2μM) for 5 min in zero extracellular Ca2+ followed by introduction of 1.8mM 
extracellular CaCl2 for a further 5 min (Lane 2 both blots). a. Cells in Lane 3-5 were exposed to the same 
protocol as Lane 2, with the exception that they were pre-incubated in either DDA (100μM; Lane 3), 2-CE 
(20μM; Lane 4) or 4-CE (20μM; Lane 5) for 15 minutes before exposure to TG.   c. Cells in Lane 3-4 were 
exposed to the same protocol as Lane 2, with the exception that they were pre-incubated in either KH7 
(20μM; Lane 3) or DDA (100μM; Lane 4) for 15 minutes before exposure to TG.    Inhibitors were then 
present throughout the experiment. The final lane in both blots is a positive control where cells were 
exposed to saturating concentrations of forskolin (20μM) and IBMX (500μM) only. Proteins within the 
homogenates were separated on 10% polyacrylamide-Tris gels. Phosphorylated VASP appears as a 
slower-migrating band in the upper panel (a, c). Blots shown representative of 3 experimental repeats. b. 
Densiometric analysis of experiments shown in a; the density of the phospho-VASP immunoreactive band 
relative to the lower (unphosphorylated) VASP band (n=3, Control vs TG/1.8Ca2+: P=0.011; TG/1.8Ca2+ vs 
DDA/TG/1.8Ca2+: P=0.892; TG/1.8Ca2+ vs 2CE/TG/1.8Ca2+: P=0.030; TG/1.8Ca2+ vs 4CE/TG/1.8Ca2+: 
P=0.026; one-way ANOVA with Student Newman Keuls post-hoc test).  d. Densiometric analysis of 
experiments shown in c; the density of the phospho-VASP immunoreactive band relative to the lower 
(unphosphorylated) VASP band (n=3, Control vs TG/1.8Ca2+: P=0.03; TG/1.8Ca2+ vs KH7/TG/1.8Ca2+: 
P=0.037; TG/1.8Ca2+ vs DDA/TG/1.8Ca2+: P=0.064 one-way ANOVA with Student Newman Keuls post-
hoc test).  
 
 
Figure 4. Cyclic AMP generated by sAC in response to SOCE phosphorylates CREB 
Immunoblot analyses of hCASMC homogenates immunoblotted with antibodies specific to the Ser133 
phospho-site on CREB (pCREB), total CREB and smooth muscle  actin (loading control).    Before being 
lysed, cells were exposed to either: vehicle control (0.1% DMSO, Lane 1 both blots) or thapsigargin (TG, 
2μM) for 5 min in zero extracellular Ca2+ followed by introduction of 1.8mM extracellular CaCl2 for a further 
5 min (Lane 2 both blots). a. Cells in Lane 3-4 were exposed to the same protocol as Lane 2, with the 
exception that they were pre-incubated in 2-CE (20μM; Lane 3) or 4-CE (20μM; Lane 4) for 15 minutes 
before exposure to TG.   c. Cells in Lane 3 were exposed to the same protocol as Lane 2, with the exception 
that they were pre-incubated in KH7 (20μM) for 15 minutes before exposure to TG.    Inhibitors were then 
present throughout the experiment. The final lane in both blots is a positive control where cells were 
exposed to saturating concentrations of forskolin (20μM) and IBMX (500μM) only. Proteins within the 
homogenates were separated on 10% polyacrylamide-Tris gels. Blots shown representative of at least 3 
experimental repeats. b. Densiometric analysis of experiments shown in a; the relative density of the 
phospho-CREB immunoreactive band (n=3, Control vs TG/1.8Ca2+: P=0.010; TG/1.8Ca2+ vs 
2CE/TG/1.8Ca2+: P=0.048; TG/1.8Ca2+ vs 4CE/TG/1.8Ca2+: P=0.023; one-way ANOVA with Student 
Newman Keuls post-hoc test). d. Densiometric analysis of experiments shown in c; the relative density of 
the phospho-CREB immunoreactive band (n=6, Control vs TG/1.8Ca2+: P=0.018; TG/1.8Ca2+ vs 
KH7/TG/1.8Ca2+: P=0.014; one-way ANOVA with Student Newman Keuls post-hoc test).  
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